Annual Reauthorization: The Yearly PA Renewal Most Patients Don't Expect

The Expiration Nobody Tells You About

Your GLP-1 prior authorization has an expiration date — typically 12 months from approval, though some plans use 6-month windows. When it expires, your pharmacy can't process refills until a new PA is approved. If you're not tracking the expiration date, you'll discover this at the pharmacy counter when your medication is suddenly denied.

Annual reauthorization is standard practice for high-cost specialty medications. It's your insurer's mechanism for confirming that continued treatment remains medically necessary. The reauthorization submission is essentially a new PA with updated clinical documentation.

Preparing for Reauthorization

Track your PA expiration date. Ask your insurer or pharmacy when your current PA expires. Mark it on your calendar with a 60-day advance reminder.

Get updated labs 30-60 days before expiration. Your reauthorization submission needs current clinical data — A1C, metabolic panel, lipid panel, and a current weight/BMI. Schedule these labs in advance so results are ready when the PA is submitted.

Schedule a prescriber visit. Your prescriber needs a recent visit documented in your chart to support the reauthorization. Many plans require a visit within 90 days of the PA submission.

Compile your year's progress. Weight trend, comorbidity improvements, medication adherence, and any side effects or dose changes. This data strengthens the reauthorization case.

What Makes Reauthorizations Succeed

Reauthorizations succeed when they demonstrate continued medical necessity and clinical benefit. The strongest submissions include: documented weight loss or weight maintenance during treatment, improvement or stabilization of comorbidities, evidence of medication adherence (consistent pharmacy fills), and a prescriber note explaining why continued treatment is medically necessary.

Reauthorizations fail when documentation is thin, labs are outdated, or the submission doesn't address the insurer's specific criteria. Don't assume that an initial approval guarantees renewal. Each reauthorization is evaluated independently.

If the Reauthorization Is Denied

A reauthorization denial follows the same appeal process as an initial denial. Your prescriber can request a peer-to-peer review, submit a formal appeal, or escalate to external review. The strongest appeal argument: "This patient has been on this medication for 12 months with documented clinical benefit. Discontinuing treatment would result in clinical regression, as demonstrated by the chronic nature of obesity and this patient's specific treatment response."

While the appeal is pending, ask your prescriber about a bridge prescription — a short-term supply to prevent a treatment gap during the review process. Some plans provide temporary coverage during active appeals.